Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Ultra-Fast Autologous CD19-Targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Systemic Lupus Erythematosus

NCT07331467 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.

NCT NCT07331467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07331467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Ultra-Fast Autologous CD19-Targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Systemic Lupus Erythematosus
Lead sponsor
Chongqing Precision Biotech Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
January 31, 2026
Completion date
August 31, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus